Assessment of Functional Status of Estrogen Receptors in Breast Cancer by Positron Emission Tomography
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02455453 |
Recruitment Status :
Completed
First Posted : May 27, 2015
Results First Posted : January 14, 2020
Last Update Posted : January 14, 2020
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
The purpose of this study is to evaluate the uptake of a radioactive tracer 21-18F-fluoro-16α,17α-[(R)-(1'-α-furylmethylidene)dioxy]-19-norpregn-4-ene-3,20-dione (FFNP) uptake, which binds to breast cancer progesterone receptors (PgRs) on a PET/CT scan before and after administration of estradiol for one day (estrogen challenge) to determine if the change in uptake is a predictor of response to endocrine therapy (ET) in patients with hormone-sensitive estrogen receptor positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Estradiol is the most potent of the naturally occurring estrogens, and can be administered to treat menopausal symptoms and also sometimes to treat metastatic breast cancer. The investigators propose to study patients with biopsy-proven newly diagnosed, locally advanced, metastatic, or recurrent breast cancer who are going to be treated with endocrine therapy (ET) (tamoxifen,aromatase inhibitors or fulvestrant as standard of care therapy.
Subjects will undergo a total of two FFNP-PET/CT scans; one before and a second one immediately following the one day estradiol challenge before the start of standard of care ET. The estradiol challenge will consist of administering a total of 6 mg of estradiol orally (three doses of 2 mg each) given at approximately 8 hour intervals and over a 24 hour period.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Breast Cancer | Drug: 18F-FFNP Device: CTI/Siemens Biograph 40 PET/CT Scanner Drug: Estradiol Drug: 18F-FDG | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 47 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Diagnostic |
Official Title: | Assessment of Functional Status of Estrogen Receptors in Breast Cancer by Positron Emission Tomography |
Actual Study Start Date : | April 28, 2015 |
Actual Primary Completion Date : | January 3, 2019 |
Actual Study Completion Date : | January 3, 2019 |

Arm | Intervention/treatment |
---|---|
Experimental: Diagnostic FFNP-PET/CT Scan
|
Drug: 18F-FFNP
Other Name: 21-18F-fluoro-16α,17α-[(R)-(1'-α-furylmethylidene)dioxy]-19-norpregn-4-ene-3,20-dione Device: CTI/Siemens Biograph 40 PET/CT Scanner
Drug: Estradiol Drug: 18F-FDG |
- Change in Primary Tumor FFNP Uptake Before and After Estradiol Challenge as Measured by Percent Change in Standardized Uptake Value (SUV) [ Time Frame: Completion of second FFNP-PET/CT scan (up to 4 weeks) ]
- Change in Secondary Tumor FFNP Uptake Before and After Estradiol Challenge as Measured by Percent Change in Standardized Uptake Value (SUV) [ Time Frame: Completion of second FFNP-PET/CT scan (up to 4 weeks) ]
- Heterogeneity of Tumor FFNP Uptake as Measured by Number of Participants With Heterogenous Response [ Time Frame: Completion of second FFNP-PET/CT scan (up to 4 weeks) ]As measured visually in known lesion by recording presence or absence of uptake with note of any changes between scans

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
-
Patient must be postmenopausal defined as meeting one or more of the following:
- Age ≥ 60 years
- Amenorrheic for at least 12 months
- Surgically sterile- having undergone bilateral oophorectomy,
- FSH level in postmenopausal range according to institutional standards (note follicle-stimulating hormone (FSH) laboratory testing must be ordered as standard of care to determine optimal treatment and should not be ordered simply to confirm eligibility to this study)
- OR Pre-menopausal for whom standard estradiol treatment (ET) is planned with ovarian suppression (imaging on study should be completed prior to start of ovarian suppression)
-
Patient must have histological or cytological confirmed breast cancer and fall into one of the following categories:
- New diagnosis with plans for at least 6 months of neoadjuvant ET or any amount of neoadjuvant ET if surgery is planned as this will be used for response assessment .
- Patients with newly diagnosed metastatic breast cancer or patient with known metastatic disease who has progressed while on therapy (no washout period is needed if the patient was treated with AIs or chemotherapy, but 2 months washout period is needed if the patient was treated with tamoxifen) who are going to be treated with ET.
-
Patient must have any one of the following types of breast cancer (primary or metastatic): ER+/PgR+/HER2- or ER+/PgR-/HER2-.
- ER+ is defined as Allred score of at least 4 and greater.
- PgR+ is defined as Allred score of at least 4 and greater.
- Immunohistochemistry (IHC) is the primary assay methodology for HER2. HER2- refers to HER2 of 0, 1+ by IHC or negative by fluorescence in situ hybridization (FISH)
-
Patient must have at least one measurable lesion according to RECIST 1.1 by radiological evaluation (ultrasound, mammography, MRI, CT, PET) or physical examination.
- Patients with evaluable osseous metastasis that are lytic or mixed lytic-sclerotic are eligible.
- Patients with hepatic lesions may be eligible provided the location of the lesion is peripheral or not too close to hepatic ducts. Decision on hepatic lesion eligibility will be made by the principal investigator or sub-investigator after careful review of all available imaging to ensure evaluation of the lesion will not be obscured by normal hepatobiliary excretion of 18F-FFNP.
- Patient must be able to understand and willing to sign a written informed consent document.
- Prior chemotherapy or endocrine therapy is allowed
- The patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 or, based on the judgment of the treating medical oncologist, can tolerate imaging and at least 6 months of ET
- The patient should have a life expectancy of > 6 months.
Exclusion Criteria:
- Patient with other invasive malignancies, with the exception of non-melanoma skin cancer or cervical carcinoma in-situ, who had (or have) any evidence of the other cancer present within the last 5 years
- Unable to tolerate up to 60 min of PET imaging per imaging session.
- Patients with non-measurable non-evaluable lesions such as pleural effusion are not eligible to participate.
- Patients with vertebral lesions that, in the opinion of the Principal Investigator and the treating medical oncologist, pose an imminent risk for cord compression.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02455453
United States, Missouri | |
Washington University School of Medicine | |
Saint Louis, Missouri, United States, 63110 |
Principal Investigator: | Farrokh Dehdashti, M.D. | Washington University School of Medicine |
Documents provided by Washington University School of Medicine:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Washington University School of Medicine |
ClinicalTrials.gov Identifier: | NCT02455453 |
Other Study ID Numbers: |
201411005 5R01CA195450-03 ( U.S. NIH Grant/Contract ) |
First Posted: | May 27, 2015 Key Record Dates |
Results First Posted: | January 14, 2020 |
Last Update Posted: | January 14, 2020 |
Last Verified: | January 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | Yes |
Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases |
Estradiol Estrogens Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs |